Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics (CMPX) with an Outperform rating and $9 price target Tovecimig has demonstrated superiority on response rate to its comparator arm in the Phase 3 COMPANION-002 study, notes the analyst, who believes it will hit statistical significance on progression-free survival with a U.S. approval in second-line biliary tract cancer during 2026. Should Tovecimig get approved, the firm thinks the launch of the drug will be “strong given the low bar” and lack of efficacy for standard chemotherapy regimens in the roughly 60% of second-line BTC patients without targetable genomic alterations, the analyst added.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
- Compass Therapeutics Confirms Directors at Annual Meeting
- Compass Therapeutics management to meet virtually with Piper Sandler
- Compass Therapeutics: Positive Drug Data and Strategic Expansion Justify Buy Rating
- Compass Therapeutics price target lowered to $10 from $12 at Guggenheim